Alkermes derives revenues from the net sales of its proprietary products — Vivitrol (alcohol and opioid dependence), Aristada ...
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report), with a price ...
Zacks.com on MSN1d
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to SayAlkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.The ...
"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback